Dozens of Palestinians killed by Israeli fire near aid centres in Gaza
Israeli gunfire and air strikes killed at least 41 Palestinians in Gaza on Wednesday, most of them at aid sites operated by the US-backed Gaza Humanitarian Foundation, local health officials said.
Health officials at Nasser Hospital in Khan Younis, in the south, said at least six of those killed had been approaching one of the aid foundation's sites in Rafah.
Medical officials at Shifa and Al Quds hospitals said at least 25 people were killed by Israeli gunfire as they approached an aid site near the former settlement of Netzarim, in the centre of the enclave, and dozens were wounded.
Health officials said another 10 people were killed in an Israeli air strike in Khan Younis, taking Wednesday's death toll to at least 41.
'We transported at least 31 martyrs and about 200 wounded as a result of Israeli tank and drone fire on thousands of citizens … on their way to receive food from the American aid centre,' Gaza civil defence spokesman Mahmud Bassal told AFP.
The Israeli military said its forces fired warning shots overnight towards suspects in the area of the Netzarim Corridor, which divides the enclave.
'This is despite warnings that the area is an active combat zone. The IDF is aware of reports regarding individuals injured; the details are under review,' it added.
A total of 163 people had already been killed and more than 1,000 wounded trying to reach the handful of aid sites operated by the foundation since it began work two weeks ago, according to Gaza's health ministry.
Mr Bassal said thousands of Palestinians had been gathering since 2am local time in the hope of reaching the food distribution centre.
'Israeli tanks fired several times, then at around 5.30am intensified their fire, coinciding with heavy fire from drones targeting civilians,' he said.
There have been a series of deadly shootings since the Gaza Humanitarian Foundation first opened aid distribution points in the Palestinian territory on May 27, after a three-month blockade. Israel had faced mounting international condemnation over the humanitarian conditions.
But UN agencies and other aid organisations have criticised the foundation, and the United Nations refuses to work with it, citing concern over its practices and neutrality.
The UN Office for the Co-ordination of Humanitarian Affairs said on Tuesday that 'Israeli military operations have intensified in recent days, with mass casualties reported".
famine and food supplies remain critically low.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The National
5 hours ago
- The National
Gaza's last major hospital faces imminent shutdown as fuel runs out
In the heart of war-torn Gaza, Al Shifa Hospital stands alone. It had been one of many medical centres providing treatment and hope during Israel's devastating bombardment of the enclave, but Kamal Adwan Hospital, the Indonesian Hospital and Al Awda Hospital have all been forced out of service. Al Shifa is now the last fully operating major hospital in Gaza. But the burden of treating the injured could soon become too much. 'We are performing the work of all the hospitals that have collapsed,' Dr Mohammed Abu Salmiya, director of Al Shifa in Gaza city, told The National. 'Our hospital was built to accommodate 140 beds. Today, we are treating over 350 patients. Most of them are lying in the corridors, in the courtyards, wherever there's floor space.' The surge in patients intensifies the pressure on a healthcare system on the brink. Inside Al Shifa, rooms meant for five patients now house more than 10. Emergency wards are overflowing. Every day, new patients, many injured in shootings near aid distribution sites, arrive in waves that overwhelm exhausted staff. But it is not only space that is running out. Medication and surgical supplies are vanishing too. 'For more than three months, not a single pill has entered Gaza,' Dr Abu Salmiya said. 'We are out of everything, drugs for surgery, painkillers, antibiotics, emergency medicine. We are treating patients without the tools we need. It is an impossible situation.' The hospital now faces most serious shortage of all. "The fuel we have can only last for a few more days,' he added. 'Yesterday, we received a small delivery, barely enough for three days. "We have appealed to the World Health Organisation, to UNDP [UN Development Programme], to anyone who can hear us. Without fuel, we will lose everyone.' The hospital desperately needs fuel to produce electricity. Without it, its generators will stop, killing patients. 'If the generators go silent, the 13 ICU patients on ventilators will die," Dr Abu Salmiya said. "Eighteen premature babies in incubators will die. The lab will shut down. And 350 kidney dialysis patients will have their treatment stopped. Their lives will be in immediate danger.' The hospital will also be forced to suspend surgical services. 'A hospital without power isn't a hospital,' he added. Across the enclave, humanitarian supplies including food and medicine are trickling in, while the healthcare system gasps for breath. But patients continue to seek help at Al Shifa. 'We're watching people die not from wounds, but from the failure of the system around them,' Dr Abu Salmiya said. 'It is no longer just war, it is the collapse of life itself.'
Zawya
7 hours ago
- Zawya
DHA grants initial approval to Yas Healthcare to set up UAE's first proton therapy centre in Dubai
The Dubai Health Authority (DHA) has accorded initial approval to Yas Healthcare, a subsidiary of Das Holding, to establish the UAE's first proton therapy centre in Dubai, marking a historic milestone in the advancement of cancer care in the region. The state-of-the-art facility is expected to be completed by late 2028, with construction slated to start in early 2026. It will be the first dedicated centre in the UAE to offer proton therapy, a highly advanced and precise form of radiation therapy that targets tumours with exceptional accuracy while sparing healthy tissue. The treatment is especially effective for paediatric cancers and tumours located near sensitive organs. Dr. Alawi Alsheikh-Ali, Director-General, Dubai Health Authority, stated, 'Under the visionary leadership of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister, and Ruler of Dubai, and H.H. Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister, Minister of Defence, and Chairman of The Executive Council of Dubai, we are committed to positioning Dubai as a global leader in healthcare. This proton therapy centre will enhance patient care, offering world-class, patient-centred treatment and improving access to specialised care that ensures better outcomes. 'This groundbreaking technology will advance cancer treatment options for our community and reinforce Dubai's goal of ranking among the top 10 cities globally for healthy life expectancy. It also strengthens Dubai's position as a key destination for advanced medical care and innovation, in line with the National Strategy for Wellbeing 2031, Dubai Social Agenda 33, and the Dubai Economic Agenda D33.' Proton therapy is a highly precise and advanced radiation treatment that delivers targeted doses to cancerous tumours while sparing surrounding healthy tissue. This minimises side effects and is particularly effective for treating paediatric cancers and complex or sensitive tumour sites. The Yas Proton Therapy Centre will provide patients across the region with access to this specialised treatment for the first time, eliminating the need to travel abroad for care. The project will be developed in strategic collaboration with the National Cancer Centre Singapore (NCCS), one of Asia's leading authorities in oncology. NCCS will serve as the project consultant, bringing global clinical and technical expertise to the design and implementation of the facility. Dr. Mohamad Zaki, Medical Director and General Manager of Yas Healthcare, said, 'Global data indicates a rising number of cancer diagnoses, particularly among younger patients. Proton therapy provides a treatment option with fewer side effects and lower toxicity for certain cancer types. The Yas Proton Therapy Centre aims to improve accessibility and reduce costs by offering this treatment closer to home.' Dr. Michael Wang, Chair of the Division of Radiation Oncology at the National Cancer Centre Singapore, added, 'This milestone collaboration with Yas Healthcare reflects the National Cancer Centre Singapore's leadership in radiation oncology, operating one of the largest proton beam facilities in Southeast Asia. We are excited to contribute our expertise as Yas Healthcare introduces this advanced technology to redefine cancer treatment in the GCC.' The move to develop the new facility directly aligns with the National Strategy for Wellbeing 2031, the Dubai Social Agenda 33, and the Dubai Economic Agenda D33 — key initiatives to enhance quality of life, improve health outcomes, and position Dubai as a premier destination for medical innovation and tourism. Dubai's Medical Tourism Vision also aims to attract more than 500,000 international patients annually by 2025. Construction work related to the project is scheduled to begin in early 2026 and the facility is expected to be operational by the end of 2028. Yas Healthcare's official platforms will provide updates on the progress of the project and patient enrolment programmes.
The National
11 hours ago
- The National
Emirati man with rare blood disorder benefits from new $2 million gene therapy in the US
An Emirati man with a rare inherited disorder has become only the second patient in the world to benefit from a pioneering $2 million gene therapy that eliminates the need for regular blood transfusions. Khalifa Dawood, 22, from Abu Dhabi said he has been given a 'new lease on life' as he recovers from the novel gene treatment he received at Cleveland Clinic Children's hospital in Ohio, which recently won medical approval for the therapy. The UAE has some of the regions highest rates of thalassaemia, also known as sickle cell disease, a condition that limits the body's ability to produce healthy red blood cells. While some carriers show very limited symptoms, others experience bone deformities, shortness of breath, dizziness, organ damage and heart palpitations. The condition can require regular blood transfusions, with research suggesting thalassaemia affects as many as 16.5 per cent of the population. A new treatment used for the first time by the Cleveland Clinic Children's hospital has proven to modify a patient's blood forming cells, and can be delivered as a one-time treatment called Casgevy. Mr Dawood said that he hoped the treatment would allow him to lead a normal life, without the need for regular hospital stays. 'I am hoping this gives me a new lease on life where I am energised to enjoy it,' he said. Life-changing treatment Since its approval by the US Food and Drug Administration in January, the therapy has been delivered to an American woman from Ohio and Mr Dawood. I am hoping this gives me a new lease on life where I am energised to enjoy it Khalifa Dawood Although the treatment is expensive, it is life changing for those who receive it, according to Dr Rabi Hanna, chairman of the paediatric haematology-oncology department at Cleveland Clinic Children's hospital. It is not uncommon for adults to receive specialist care at a children's centre, particularly for conditions they have had since birth, as is the case with Mr Dawood. 'Unlike regular medicines that people take for years, Casgevy is meant to be a one-time treatment that could last a lifetime,' he said. 'It uses CRISPR gene editing, which is a very advanced science. Editing cells safely and precisely takes a lot of time, technology, and testing. 'It is also custom-made, as Casgevy is made from a person's own cells, which are collected, sent to a lab, edited and then returned. That process is complex and individualised.' The innovative treatment uses a gene editing technology called CRISPR/Cas9 to modify a patient's stem cells. The edited cells are then transplanted back into the patient, where they produce more haemoglobin in new healthy red blood cells. The FDA's approval was based on results from a single arm which showed 91 per cent of patients with beta thalassaemia did not need a blood transfusion for at least a year after having the treatment. Costly medical care Despite the therapy's success, it is likely to remain out of reach for the majority with costs of about $2.2 million. Gene therapies are typically the most expensive medical treatments. Etranacogene dezaparvovec, sold under the brand name Hemgenix is a gene therapy used for the treatment of haemophilia B, a potentially life threatening disorder that prevents blood from clotting. Priced at about $3.5 million, it was the world's most expensive drug until the arrival of Lenmeldy in March last year. The gene treatment developed by Orchard Therapeutics costs about $4.2 million and is used to treat life threatening nerve disorders in young children. High costs of certain drugs can be covered by insurers, government health systems or charitable foundations when there are no other treatment options. Drug companies also occasionally offer financial support programmes for families in need. The process of administering Casgevy begins by collecting stem cells from the patient's blood that are then sent to the lab to be edited using tiny, precise scissors. By clipping off the DNA responsible for preventing the body making healthy haemoglobin, the repaired cells can then be returned to the body. A course of chemotherapy is then required to clear out the old, sick marrow cells, allowing new healthy ones to grow in their place. Recovery time in the hospital is about four weeks. As the science behind gene editing improves, it should become faster, easier and cheaper to edit cells with higher accuracy, and fewer side effects. 'It is my hope and prediction that price will come down, but I am not sure how quickly,' said Dr Hanna. 'As the science of gene editing improves, it may become faster, easier, and cheaper to edit cells with higher accuracy and fewer side effects. 'Right now, Casgevy is the first gene editing therapy approved for sickle cell and thalassaemia. 'But more companies are developing similar treatments. When that happens, competition can help drive prices down. 'Also as companies learn how to make these therapies at scale, they may reduce production and delivery costs. 'Think of it like early computers or smartphones – they were expensive at first, but prices dropped as technology improved.' Global health drive Although patients like Mr Dawood must travel overseas for expensive gene therapy, the Gulf is also emerging as a go-to destination for emerging treatments. The King Faisal Specialist Hospital & Research Centre in Saudi Arabia is emerging as a leader of regional clinical trials and delivered a breakthrough in haemophilia care, using one-time gene therapy to restore clotting function in eight patients. In the UAE, at Medcare Royal Speciality Hospital Al Qusais, patients are receiving the latest care for rare genetic disorders like spinal muscular atrophy and Duchenne muscular dystrophy, two life-limiting growth conditions. Doctors there said patients were travelling into Dubai from Turkey and elsewhere in the region. Medcare Women and Children Hospital was one of the first private clinics outside the US to administer gene therapy for spinal muscular atrophy, and has since delivered 100 infusions. American Hospital, Al Jalila Children's Hospital and Fakeeh University Hospital also offer gene therapy Zolgensma, which can cost about $2 million per dose. Dr Vivek Mundada, a consultant paediatric neurologist at Medcare Royal Speciality Hospital, said the drug had delivered remarkable outcomes in managing complex genetic conditions. 'Dubai is becoming a centre of medical innovation, and Medcare is proud to be leading that movement, especially in the field of rare genetic diseases,' he said. 'Through our comprehensive, patient-centred care model, we are transforming outcomes for children who previously had limited treatment options.'
